SG133603A1 - Thalidomide analogs as tnf-alpha modulators - Google Patents
Thalidomide analogs as tnf-alpha modulatorsInfo
- Publication number
- SG133603A1 SG133603A1 SG200704530-5A SG2007045305A SG133603A1 SG 133603 A1 SG133603 A1 SG 133603A1 SG 2007045305 A SG2007045305 A SG 2007045305A SG 133603 A1 SG133603 A1 SG 133603A1
- Authority
- SG
- Singapore
- Prior art keywords
- tnf
- thalidomide analogs
- alpha modulators
- modulators
- alpha
- Prior art date
Links
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical class O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
- C07D211/86—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
- C07D211/86—Oxygen atoms
- C07D211/88—Oxygen atoms attached in positions 2 and 6, e.g. glutarimide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US50472403P | 2003-09-17 | 2003-09-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG133603A1 true SG133603A1 (en) | 2007-07-30 |
Family
ID=34375538
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG200704530-5A SG133603A1 (en) | 2003-09-17 | 2004-09-17 | Thalidomide analogs as tnf-alpha modulators |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US7973057B2 (enExample) |
| EP (1) | EP1663223B1 (enExample) |
| JP (1) | JP4943845B2 (enExample) |
| CN (1) | CN1867331B (enExample) |
| AU (1) | AU2004274474B2 (enExample) |
| BR (1) | BRPI0414497A (enExample) |
| CA (2) | CA2808646C (enExample) |
| SG (1) | SG133603A1 (enExample) |
| WO (1) | WO2005028436A2 (enExample) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2929331B2 (ja) * | 1990-07-18 | 1999-08-03 | 丸善石油化学株式会社 | トラクションドライブ用流体 |
| KR101389246B1 (ko) | 2004-07-15 | 2014-04-24 | 브리스톨-마이어스스퀴브컴파니 | 아릴- 및 헤테로아릴-치환된 테트라히드로이소퀴놀린, 및 이것의 노르에피네프린, 도파민 및 세로토닌의 재흡수를 차단하기 위한 용도 |
| CN100383139C (zh) * | 2005-04-07 | 2008-04-23 | 天津和美生物技术有限公司 | 可抑制细胞释放肿瘤坏死因子的哌啶-2，6-二酮衍生物 |
| CN1939922B (zh) * | 2005-09-27 | 2010-10-13 | 天津和美生物技术有限公司 | 可抑制细胞释放肿瘤坏死因子的5H-噻吩[3，4-c]吡咯-4，6-二酮衍生物 |
| US20080064876A1 (en) * | 2006-05-16 | 2008-03-13 | Muller George W | Process for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione |
| US8877780B2 (en) | 2006-08-30 | 2014-11-04 | Celgene Corporation | 5-substituted isoindoline compounds |
| JP5523831B2 (ja) * | 2006-08-30 | 2014-06-18 | セルジーン コーポレイション | ５−置換イソインドリン化合物 |
| AU2013260742B2 (en) * | 2007-03-20 | 2016-06-16 | Celgene Corporation | 4'-o-substituted isoindoline derivatives and compositions comprising and methods of using the same |
| KR101791757B1 (ko) * | 2007-03-20 | 2017-10-30 | 셀진 코포레이션 | 4'-ｏ-치환된 아이소인돌린 유도체 및 이를 포함하는 조성물 및 이의 사용 방법 |
| US7723301B2 (en) * | 2007-08-29 | 2010-05-25 | The Board Of Trustees Of The University Of Arkansas | Pharmaceutical compositions comprising an anti-teratogenic compound and applications of the same |
| WO2009139880A1 (en) * | 2008-05-13 | 2009-11-19 | Celgene Corporation | Thioxoisoindoline compounds and compositions and methods of using the same |
| US9156812B2 (en) | 2008-06-04 | 2015-10-13 | Bristol-Myers Squibb Company | Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine |
| KR101830447B1 (ko) * | 2009-05-12 | 2018-02-20 | 알바니 몰레큘라 리써치, 인크. | 7-(［1,2,4］트리아졸로［1,5-α］피리딘-6-일)-4-(3,4-디클로로페닐)-1,2,3,4-테트라하이드로이소퀴놀린 및 이의 용도 |
| CN102638982B (zh) | 2009-05-12 | 2015-07-08 | 百时美施贵宝公司 | (S)-7-([1,2,4]三唑并[1,5-a]吡啶-6-基)-4-(3,4-二氯苯基)-1,2,3,4-四氢异喹啉的晶型及其用途 |
| EP2429295B1 (en) | 2009-05-12 | 2013-12-25 | Albany Molecular Research, Inc. | Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof |
| PL2536706T3 (pl) | 2010-02-11 | 2017-10-31 | Celgene Corp | Pochodne arylometoksyizoindoliny i zawierające je kompozycje oraz sposoby ich zastosowania |
| ES2664872T3 (es) | 2010-06-18 | 2018-04-23 | Taiho Pharmaceutical Co., Ltd | Moduladores PRPK-TPRKB y sus usos |
| US8927725B2 (en) | 2011-12-02 | 2015-01-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Thio compounds |
| WO2013089278A1 (en) | 2011-12-14 | 2013-06-20 | Taiho Pharmaceutical Co., Ltd. | Recombinant prpk-tprkb and uses thereof |
| US9383644B2 (en) | 2014-09-18 | 2016-07-05 | Heraeus Precious Metals North America Daychem LLC | Sulfonic acid derivative compounds as photoacid generators in resist applications |
| NZ731789A (en) | 2014-10-30 | 2019-04-26 | Kangpu Biopharmaceuticals Ltd | Isoindoline derivative, intermediate, preparation method, pharmaceutical composition and use thereof |
| US9477150B2 (en) | 2015-03-13 | 2016-10-25 | Heraeus Precious Metals North America Daychem LLC | Sulfonic acid derivative compounds as photoacid generators in resist applications |
| JP6930969B2 (ja) * | 2015-07-08 | 2021-09-01 | ギルローズ ファーマシューティカルズ，リミティド ライアビリティ カンパニー | 前頭前皮質プロセシング疾患、歩行及び四肢障害の治療 |
| CA3000661C (en) | 2015-09-30 | 2024-04-02 | Nigel H. Greig | Thalidomide analogs and methods of use |
| US11395820B2 (en) | 2016-03-16 | 2022-07-26 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Small molecules against cereblon to enhance effector t cell function |
| CN108101887A (zh) * | 2016-11-24 | 2018-06-01 | 天津和美生物技术有限公司 | 哌啶-2,6-二酮衍生物及其在治疗克罗恩氏病中的用途 |
| US11999802B2 (en) | 2017-10-18 | 2024-06-04 | Novartis Ag | Compositions and methods for selective protein degradation |
| SG11202012464WA (en) | 2018-07-11 | 2021-01-28 | H Lee Moffitt Cancer Center And Research Institute Inc | Dimeric immuno-modulatory compounds against cereblon-based mechanisms |
| US11324731B2 (en) | 2018-09-13 | 2022-05-10 | City Of Hope | TXNIP-TRX complex inhibitors and methods of using the same |
| AU2019381688A1 (en) | 2018-11-13 | 2021-06-03 | Biotheryx, Inc. | Substituted isoindolinones |
| WO2020124500A1 (zh) * | 2018-12-20 | 2020-06-25 | 江苏凯迪恩医药科技有限公司 | 一种含氮杂环化合物、其制备方法及应用 |
| EP3959320A1 (en) | 2019-04-24 | 2022-03-02 | Novartis AG | Compositions and methods for selective protein degradation |
| CN112321566B (zh) | 2019-08-05 | 2022-06-10 | 上海科技大学 | Egfr蛋白降解剂及其抗肿瘤应用 |
| AU2020336381A1 (en) * | 2019-08-27 | 2022-03-03 | The Regents Of The University Of Michigan | Cereblon E3 ligase inhibitors |
| KR102783667B1 (ko) | 2019-10-24 | 2025-03-21 | 삼성전자 주식회사 | 전자 장치 및 그의 디스플레이 동작 제어 방법 |
| US12441707B2 (en) | 2019-12-30 | 2025-10-14 | Tyra Biosciences, Inc. | Indazole compounds |
| TW202140448A (zh) * | 2020-01-16 | 2021-11-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 並環醯亞胺類衍生物、其製備方法及其在醫藥上的應用 |
| KR102833592B1 (ko) * | 2020-02-25 | 2025-07-15 | 상하이테크 유니버시티 | 글루타르이미드 골격을 기초로 하는 화합물 및 그 응용 |
| KR20220055171A (ko) * | 2020-10-26 | 2022-05-03 | 주식회사 아이비스바이오 | 포말리도마이드로부터 3,6'-디티오포말리도마이드를 선택적으로 합성하는 방법 |
| US20240166647A1 (en) * | 2021-03-03 | 2024-05-23 | The Regents Of The University Of Michigan | Cereblon Ligands |
| WO2023163538A1 (ko) * | 2022-02-25 | 2023-08-31 | 주식회사 아이비스바이오 | 신규한 포말리도마이드 유도체, 이의 제조방법 및 용도 |
| AR130961A1 (es) | 2022-11-04 | 2025-02-05 | Bristol Myers Squibb Co | Compuestos y su uso para el tratamiento de hemoglobinopatías |
| WO2025016351A1 (zh) * | 2023-07-14 | 2025-01-23 | 标新生物医药科技(上海)有限公司 | 基于硫代的戊二酰亚胺基异吲哚啉酮骨架的化合物及其应用 |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2830991A (en) * | 1954-05-17 | 1958-04-15 | Gruenenthal Chemie | Products of the amino-piperidine-2-6-dione series |
| GB962857A (en) | 1961-12-04 | 1964-07-08 | Distillers Co Yeast Ltd | Process for the production of imides |
| GB1049283A (en) | 1962-04-14 | 1966-11-23 | Distillers Co Yeast Ltd | Substituted butyro-lactones and -thiolactones |
| US3320270A (en) * | 1963-10-08 | 1967-05-16 | Tri Kem Corp | Certain 2-acylimidothiazole compounds |
| US3314953A (en) * | 1964-03-16 | 1967-04-18 | Richardson Merrell Inc | 1-substituted-3-phthalimido-2, 5-dioxopyrrolidines |
| US3560495A (en) * | 1965-05-08 | 1971-02-02 | Ernst Frankus | 1-heterocyclic amino methyl or 1-heterocyclic hydrazino methyl-3-phthalimido or (3',6'-dithia-3',4',5',6'-tetrahydrophthalimido)-pyrrolidinediones-2,5 or piperidinediones-2,6 |
| IL25595A (en) | 1965-05-08 | 1971-01-28 | Gruenenthal Chemie | New history of cyclic amide compounds and process for the production of these compounds |
| GB1324718A (en) * | 1970-11-10 | 1973-07-25 | Nehezvegyipari Kutato Intezet | Phthalimido triazines |
| US4067718A (en) * | 1975-11-12 | 1978-01-10 | American Cyanamid Company | Method for controlling the relative stem growth of plants |
| US4291048A (en) * | 1978-07-06 | 1981-09-22 | Joseph Gold | Method of treating tumors and cancerous cachexia with L-tryptophan |
| US5354690A (en) * | 1989-07-07 | 1994-10-11 | Karl Tryggvason | Immunological methods for the detection of the human type IV collagen α5 chain |
| US5902790A (en) | 1995-10-03 | 1999-05-11 | Cytran, Inc. | Pharmaceutical angiostatic dipeptide compositions and method of use thereof |
| GB9311281D0 (en) * | 1993-06-01 | 1993-07-21 | Rhone Poulenc Rorer Ltd | Novel composition of matter |
| AU661299B2 (en) | 1991-04-17 | 1995-07-20 | Grunenthal Gmbh | New thalidomide derivatives, method of manufacture and use thereof in medicaments |
| US6096768A (en) * | 1992-01-28 | 2000-08-01 | Rhone-Poulenc Rorer Limited | Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group |
| US20010056114A1 (en) * | 2000-11-01 | 2001-12-27 | D'amato Robert | Methods for the inhibition of angiogenesis with 3-amino thalidomide |
| US5629327A (en) * | 1993-03-01 | 1997-05-13 | Childrens Hospital Medical Center Corp. | Methods and compositions for inhibition of angiogenesis |
| US6228879B1 (en) * | 1997-10-16 | 2001-05-08 | The Children's Medical Center | Methods and compositions for inhibition of angiogenesis |
| US5434170A (en) | 1993-12-23 | 1995-07-18 | Andrulis Pharmaceuticals Corp. | Method for treating neurocognitive disorders |
| US5443824A (en) * | 1994-03-14 | 1995-08-22 | Piacquadio; Daniel J. | Topical thalidomide compositions for surface or mucosal wounds, ulcerations, and lesions |
| DE4422237A1 (de) * | 1994-06-24 | 1996-01-04 | Gruenenthal Gmbh | Verwendung von Lactamverbindungen als pharmazeutische Wirkstoffe |
| US5789434A (en) * | 1994-11-15 | 1998-08-04 | Bayer Corporation | Derivatives of substituted 4-biarylbutyric acid as matrix metalloprotease inhibitors |
| RU2164514C2 (ru) | 1994-12-30 | 2001-03-27 | Селджин Корпорейшн | Имид/амидные простые эфиры, фармацевтическая композиция на их основе и способ снижения уровня фнока у млекопитающих |
| US6429221B1 (en) | 1994-12-30 | 2002-08-06 | Celgene Corporation | Substituted imides |
| US5783605A (en) * | 1995-02-27 | 1998-07-21 | Kuo; Sheng-Chu | Helper inducers for differentiation therapy and chemoprevention of cancer |
| US5728844A (en) | 1995-08-29 | 1998-03-17 | Celgene Corporation | Immunotherapeutic agents |
| CA2251060C (en) | 1996-04-09 | 2006-09-12 | Grunenthal Gmbh | Acylated n-hydroxy methyl thalidomide prodrugs with immunomodulator action |
| DE19613976C1 (de) | 1996-04-09 | 1997-11-20 | Gruenenthal Gmbh | Thalidomid-Prodrugs mit immunmodulatorischer Wirkung |
| CA2256669A1 (en) | 1996-05-29 | 1997-12-04 | Prototek, Inc. | Prodrugs of thalidomide and methods for using same as modulators of t-cell function |
| DE69739802D1 (de) | 1996-07-24 | 2010-04-22 | Celgene Corp | Substituierte 2-(2,6-Dioxopiperidine-3-yl)-phthalimide -1-oxoisoindoline und Verfahren zur Reduzierung des TNF-alpha Spiegels |
| US5635517B1 (en) * | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
| EP1586322B1 (en) | 1996-11-05 | 2008-08-20 | The Children's Medical Center Corporation | Compositions comprising thalodimide and dexamethasone for the treatment of cancer& x9; |
| EP0944594A4 (en) | 1996-12-13 | 2000-05-03 | Lilly Co Eli | INHIBITORS OF THE PSA ANTIGEN ENZYMATIC ACTIVITY |
| DE19703763C1 (de) | 1997-02-01 | 1998-10-01 | Gruenenthal Gmbh | Thalidomidanaloge Verbindungen aus der Klasse der Piperidin-2,6-Dione |
| RU2108786C1 (ru) | 1997-09-15 | 1998-04-20 | Клавдия Степановна Евланенкова | Средство для лечения онкологических больных |
| DE19743968C2 (de) * | 1997-10-06 | 2002-07-11 | Gruenenthal Gmbh | Intravenöse Applikationsform von Thalidomid zur Therapie immunologischer Erkrankungen |
| AU749356B2 (en) | 1998-05-11 | 2002-06-27 | Children's Medical Center Corporation | Analogs of 2-phthalimidinoglutaric acid and their use as inhibitors of angiogenesis |
| AU748397B2 (en) | 1998-05-15 | 2002-06-06 | Astrazeneca Ab | Benzamide derivatives for the treatment of diseases mediated by cytokines |
| DE19843793C2 (de) * | 1998-09-24 | 2000-08-03 | Gruenenthal Gmbh | Substituierte Benzamide |
| US20030013739A1 (en) * | 1998-12-23 | 2003-01-16 | Pharmacia Corporation | Methods of using a combination of cyclooxygenase-2 selective inhibitors and thalidomide for the treatment of neoplasia |
| PT1040838E (pt) | 1999-03-31 | 2003-08-29 | Gruenenthal Gmbh | Solucao aquosa estavel de 3-(1-oxo-1,3-di-hidro-isoindol-2-il)piperidino-2,6-diona |
| WO2001041755A2 (en) * | 1999-12-02 | 2001-06-14 | The Regents Of The University Of Michigan | Topical compositions comprising thalidomide for the treatment of inflammatory diseases |
| US6458810B1 (en) * | 2000-11-14 | 2002-10-01 | George Muller | Pharmaceutically active isoindoline derivatives |
| CA2430669C (en) | 2000-11-30 | 2011-06-14 | The Children's Medical Center Corporation | Synthesis of 3-amino-thalidomide and its enantiomers |
| US20030045552A1 (en) * | 2000-12-27 | 2003-03-06 | Robarge Michael J. | Isoindole-imide compounds, compositions, and uses thereof |
| EP1389203B8 (en) * | 2001-02-27 | 2010-03-10 | The Governement of the United States of America, represented by The Secretary Department of Health and Human services | Analogs of thalidomide as angiogenesis inhibitors |
| WO2003014315A2 (en) | 2001-08-06 | 2003-02-20 | The Children's Medical Center Corporation | Synthesis and anti-tumor activity of nitrogen substituted thalidomide analogs |
| EP1336602A1 (en) * | 2002-02-13 | 2003-08-20 | Giovanni Scaramuzzino | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases |
| CN1981761B (zh) | 2002-05-17 | 2011-10-12 | 细胞基因公司 | 使用免疫调节性化合物用于制备治疗和控制癌症和其它疾病药物中的应用及组合物 |
| CN100488959C (zh) | 2003-03-27 | 2009-05-20 | 天津和美生物技术有限公司 | 水溶性的酞胺哌啶酮衍生物 |
| WO2005016326A2 (en) | 2003-07-11 | 2005-02-24 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Analogs of thalidomide as potential angiogenesis inhibitors |
-
2004
- 2004-09-17 CA CA2808646A patent/CA2808646C/en not_active Expired - Fee Related
- 2004-09-17 CN CN2004800268113A patent/CN1867331B/zh not_active Expired - Fee Related
- 2004-09-17 SG SG200704530-5A patent/SG133603A1/en unknown
- 2004-09-17 BR BRPI0414497-0A patent/BRPI0414497A/pt not_active IP Right Cessation
- 2004-09-17 WO PCT/US2004/030506 patent/WO2005028436A2/en not_active Ceased
- 2004-09-17 CA CA2538864A patent/CA2538864C/en not_active Expired - Fee Related
- 2004-09-17 AU AU2004274474A patent/AU2004274474B2/en not_active Ceased
- 2004-09-17 EP EP04784385.9A patent/EP1663223B1/en not_active Expired - Lifetime
- 2004-09-17 JP JP2006527059A patent/JP4943845B2/ja not_active Expired - Fee Related
- 2004-09-17 US US10/572,485 patent/US7973057B2/en not_active Expired - Fee Related
-
2011
- 2011-06-03 US US13/153,355 patent/US8546430B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US20060211728A1 (en) | 2006-09-21 |
| CA2538864A1 (en) | 2005-03-31 |
| CN1867331B (zh) | 2010-05-26 |
| WO2005028436A3 (en) | 2005-05-19 |
| AU2004274474A1 (en) | 2005-03-31 |
| JP2007505922A (ja) | 2007-03-15 |
| CA2538864C (en) | 2013-05-07 |
| CA2808646A1 (en) | 2005-03-31 |
| US8546430B2 (en) | 2013-10-01 |
| AU2004274474B2 (en) | 2011-03-10 |
| JP4943845B2 (ja) | 2012-05-30 |
| US7973057B2 (en) | 2011-07-05 |
| EP1663223A2 (en) | 2006-06-07 |
| EP1663223B1 (en) | 2014-01-01 |
| US20110245210A1 (en) | 2011-10-06 |
| CN1867331A (zh) | 2006-11-22 |
| WO2005028436A2 (en) | 2005-03-31 |
| BRPI0414497A (pt) | 2006-11-14 |
| CA2808646C (en) | 2016-08-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG133603A1 (en) | Thalidomide analogs as tnf-alpha modulators | |
| ZA200700357B (en) | Tetrapetide analogs | |
| IL172030A0 (en) | Hydrogel composition demonstrating phase separation | |
| GB0304424D0 (en) | Novel compounds | |
| EP1596860A4 (en) | NEW CONNECTIONS | |
| IL170742A0 (en) | Somatostatin-dopamine chimeric analogs | |
| GB0323258D0 (en) | Therapeutic compounds | |
| GB0324201D0 (en) | Improved antitumoral combinations | |
| GB2407131B (en) | Modulator | |
| EP1648885A4 (en) | NEW CONNECTIONS | |
| GB0306575D0 (en) | Modulators | |
| EP1599174A4 (en) | NEW CONNECTIONS | |
| HU0401176D0 (en) | Prokinetic pharmaceutical composition | |
| GB0427954D0 (en) | Modulator | |
| GB0318336D0 (en) | Antitumoral compounds | |
| GB0314304D0 (en) | Antitumoral compounds | |
| GB0314724D0 (en) | Antitumoral compounds | |
| GB0307657D0 (en) | Antitumoral compounds | |
| GB0326067D0 (en) | Antitumoral compounds | |
| GB0327279D0 (en) | Antitumoral compounds | |
| GB2397449B (en) | Modulator | |
| GB0314725D0 (en) | New antitumoral compounds | |
| GB0330175D0 (en) | Haynet filling aid | |
| GB0425829D0 (en) | Antitumoral compounds | |
| GB0424964D0 (en) | Antitumoral compounds |